Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 18/20 | 0.71 |
| ▸ | HSP90AB1 | P08238 | 11/20 | 0.71 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1019221 | 0.93 | HSP90AA1 (0.71) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL1019008 | 0.93 | HSP90AB1 (0.63) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL1018626 | 0.92 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL15703773 | 0.89 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL15182471 | 0.88 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL1018432 | 0.87 | HSP90AA1 (0.80) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL1019455 | 0.86 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL13649822 | 0.85 | HSP90AA1 (0.71) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL12855315 | 0.85 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 | |
| SCHEMBL1019009 | 0.85 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1HSP90B1HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271618-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2014-05-21 | — | — | EP | claimed |
| US-20130210820-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-15 | — | — | US | claimed |
| US-8383619-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-02-26 | — | — | US | claimed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | claimed |
| EP-2271618-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2014-05-21 | — | — | EP | disclosed |
| EP-2271618-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2014-05-21 | — | — | EP | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-8664218-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD. (GB) | 2014-03-04 | — | — | US | disclosed |
| US-20130210820-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-15 | — | — | US | disclosed |
| US-20130210820-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-15 | — | — | US | disclosed |
| US-20130210820-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-15 | — | — | US | disclosed |
| US-8383619-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-8383619-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2271618-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009125230-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009125230-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210820-A1 | Pharmaceutical Compounds | SLC10A1, MAPT, SLC5A1 | HSP90AA1 2662/4885HSP90AB1 2096/4885HSP90B1 3472/4885 |
| US-20110098290-A1 | PHARMACEUTICAL COMPOUNDS | NR3C2, NR5A2, NR0B1 | HSP90AA1 4129/4885HSP90AB1 3671/4885HSP90B1 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.